HIV-1 Tat: coping with negative elongation factors. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


HIV-1 Tat: coping with negative elongation factors.

Curr Opin Immunol. 1999 Aug;11(4):460-5. Unique Identifier : AIDSLINE MED/99379881
Garber ME; Jones KA; Regulatory Biology Laboratory, The Salk Institute, 10010 North; Torrey Pines Road, La Jolla, CA 92037-1099, USA.

Abstract: The intrinsic processivity of RNA polymerase II complexes arises from a complex interplay between the recently identified positive transcription elongation factor b (P-TEFb) and negative transcription elongation factors, DSIF (5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole [DRB]-sensitivity-inducing factor) and the negative elongation factor complex (NELF). Elements in nascent HIV-1 RNA function in concert with these factors and the HIV-1 Tat protein to ensure that viral transcription is induced strongly in activated T cells. Studies in the past year have elucidated key aspects of the Tat trans-activation mechanism that help to define this important paradigm for RNA-mediated control of transcription elongation.
Keywords: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Animal Gene Products, tat/*PHYSIOLOGY Human HIV-1/*GENETICS Peptide Elongation Factors/*PHYSIOLOGY Promoter Regions (Genetics) Protein-Serine-Threonine Kinases/*PHYSIOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Trans-Activation (Genetics) Transcription, GeneticKWDjournalarticlereviewreview,tutorialanimalgeneproducts,tat/KWDphysiologyhumanhiv-1/KWDgeneticspeptideelongationfactors/KWDphysiologypromoterregions(genetics)protein-serine-threoninekinases/KWDphysiologysupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDtrans-activation(genetics)transcription,genetic
991130
A99B1128

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .